People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Relation Therapeutics Inc. | — | Biotechnology | Series C | $116.4M | $189.9M | 2022 |
Jason Benjamin Pontin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jason Benjamin Pontin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jason Pontin | 1 | 5 |
| Christine Aylward | 1 | 4 |
| Jim Mellon | 1 | 4 |
| Charles Roberts | 1 | 4 |
| David Roblin | 1 | 3 |
| Casey Swerner | 1 | 1 |
| Jim Benjamin Mellon | 1 | 1 |
| Christine Benjamin Aylward | 1 | 1 |
| Casey Benjamin Swerner | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.